Highlander Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Highlander Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-14,000	Closed	-$125K	–	766
2017 Q2	$125K	Sell	14,000 -2,500	-15%	-$16K	0.1%	219
2017 Q1	$86K	Sell	16,500 -1,000	-6%	-$4.01K	0.07%	267
2016 Q4	$53K	Sell	17,500 -20,500	-54%	-$74.6K	0.05%	322
2016 Q3	$176K	Sell	38,000 -5,000	-12%	-$25.4K	0.16%	166
2016 Q2	$249K	Sell	43,000 -1,000	-2%	-$6.37K	0.23%	125
2016 Q1	$266K	Sell	44,000 -9,000	-17%	-$54K	0.25%	114
2015 Q4	$484K	Sell	53,000 -5,600	-10%	-$43.2K	0.45%	56
2015 Q3	$330K	Buy	58,600 +15,100	+35%	+$125K	0.31%	88
2015 Q2	$482K	Buy	43,500 +36,000	+480%	+$464K	0.43%	61
2015 Q1	$118K	Buy	+7,500	New	+$116K	0.1%	227

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highlander Capital Management's SGMO Position: Q3 2017 in Review

Highlander Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2017, closing a stake of 14,000 shares — an estimated $125K sold.

Highlander Capital Management first reported a position in SGMO in Q1 2015 and held it in 10 quarters. The position peaked at $484K in Q4 2015. 148 funds tracked by Wall St. Rank hold SGMO as of Q3 2017.

Highlander Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2017 after selling out during the quarter.
Highlander Capital Management sold 14,000 SANGAMO THERAPEUTICS INC shares in Q3 2017, an estimated $125K.
Highlander Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2015 and held it in 10 quarters.
Highlander Capital Management's SANGAMO THERAPEUTICS INC position peaked at $484K in Q4 2015.
148 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2017.

Based on Highlander Capital Management's 13F filing for Q3 2017, filed 15 Nov 2017.